Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up
Mathias Due Buron(Rigshospitalet), Melinda Magyari(University of Copenhagen), Peter Vestergaard Rasmussen(Aarhus University Hospital), Luigi Pontieri(Rigshospitalet), Per Soelberg Sørensen(University of Copenhagen), Jeppe Romme Christensen(Copenhagen University Hospital), Danny Bech(Regionshospitalet Viborg), Finn Sellebjerg(Kaiser Permanente), Hanna Joensen(Rigshospitalet), Matthias Kant(Sygehus Sønderjylland)
Cited by 6
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|957